Does Apellis Pharmaceuticals Inc (NASDAQ:APLS) Have Gas After Even Less Sellers Involved?

June 18, 2018 - By Kenneth Lin

The stock of Apellis Pharmaceuticals Inc (NASDAQ:APLS) registered a decrease of 8.16% in short interest. APLS’s total short interest was 1.64M shares in June as published by FINRA. Its down 8.16% from 1.79M shares, reported previously. With 514,900 shares average volume, it will take short sellers 3 days to cover their APLS’s short positions. The short interest to Apellis Pharmaceuticals Inc’s float is 6.98%.

The stock increased 1.20% or $0.27 during the last trading session, reaching $22.7. About 73,290 shares traded. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 0.00% since June 18, 2017 and is . It has underperformed by 12.57% the S&P500.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The company has market cap of $1.27 billion. The Company’s lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. It currently has negative earnings. The firm develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration.

More notable recent Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news were published by: Benzinga.com which released: “44 Biggest Movers From Yesterday” on May 22, 2018, also Nasdaq.com with their article: “Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference” published on May 31, 2018, Streetinsider.com published: “UPDATE: Cantor Fitzgerald Starts Apellis Pharmaceuticals (APLS) at Overweight” on May 23, 2018. More interesting news about Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on May 24, 2018 as well as Benzinga.com‘s news article titled: “32 Stocks Moving In Monday’s Mid-Day Session” with publication date: May 21, 2018.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: